Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 8:10.1007/s00256-024-04859-1.
doi: 10.1007/s00256-024-04859-1. Online ahead of print.

Imaging and management of calcium pyrophosphate deposition disease

Affiliations
Review

Imaging and management of calcium pyrophosphate deposition disease

Wasim Issa et al. Skeletal Radiol. .

Abstract

The radiological manifestations of calcium pyrophosphate deposition (CPPD) revolve around two main axes: the asymptomatic form and CPPD disease. The latter is a consequence of an immune response to calcium phosphate crystals. Chondrocalcinosis is broadly considered the radiographic manifestation of CPPD regardless of whether it is asymptomatic or associated with inflammatory arthritis. CPPD is associated with osteoarthritis although the direction of such association is still unclear. Apart from the detection of CPP crystals in synovial fluid, imaging (mainly conventional radiography and increasingly ultrasound) plays a central role in the diagnosis of CPPD disease. Recently, CT has been added as a diagnostic tool, especially in deep anatomic locations such as crowned dens. To date, no treatment is effective in dissolving CPP crystals. For now, the focus of current treatment strategies remains inflammation control. Our aim is to review the epidemiology, pathogenesis, and clinical and imaging manifestations of asymptomatic and symptomatic CPPD. We will also discuss recent consensus definitions and classifications of CPPD disease.

Keywords: CPPD; Calcium crystal; Calcium pyrophosphate; Osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: A.G. is shareholder of BICL, LLC and consultant to Novartis, TissueGene, Coval, Medipost, Formation Bio, Pacira, ICM, Levicept, 4Moving Biotech, Peptinov, and Scarcell Therapeutics. W.I., J.Y. and M.J and have no conflict of interest.

Similar articles

References

    1. Kohn NN The Significance of Calcium Phosphate Crystals in the Synovial Fluid of Arthritic Patients: The ‘Pseudogout Syndrome’: II. Identification of Crystals. Ann. Intern. Med 56, 738 (1962). - PubMed
    1. Jarraya M, Roemer F, Kwoh CK & Guermazi A Crystal arthropathies and osteoarthritis—where is the link? Skeletal Radiol. 52, 2037–2043 (2023). - PubMed
    1. Abhishek A et al. The 2023 ACR/ EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis Rheumatol. 75, 1703–1713 (2023). - PMC - PubMed
    1. Neame RL UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann. Rheum. Dis 62, 513–518 (2003). - PMC - PubMed
    1. Felson DT et al. Risk factors for incident radiographic knee osteoarthritis in the elderly. The framingham study. Arthritis Rheum. 40, 728–733 (1997). - PubMed

LinkOut - more resources